PBH vs AMLX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PBH · Prestige Consumer Healthcare$49.63 ▲ 0.06%
AMLX · Amylyx Pharmaceuticals$26.02 ▼ 0.69%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PBH -13.6%
- AMLX +75.6%
Head to head
| Metric | PBH | AMLX |
|---|---|---|
| Price | $49.63 | $26.02 |
| Change today | ▲ 0.06% | ▼ 0.69% |
| Market cap | $2.35B | $3.35B |
| Return, 3 months | -4.6% | -31.8% |
| Return, year to date | -19.5% | +115.4% |
| Return, 1 year | -16.5% | +77.4% |
| P/E (TTM) | 15.3 | – |
| P/B | 1.2 | 4.4 |
| P/E percentile vs own 5y | 39th | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +22.7% | – |
| Net profit growth (YoY) | -40.1% | -32.3% |
| Gross margin | 52.5% | – |
| Operating margin | 25.0% | – |
| Net margin | 13.3% | – |
| Return on equity | 8.2% | -30.1% |
| Analyst target vs. price | +41.0% | +77.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 56 | 39 |
| 30-day volatility | 67.1% | 58.0% |
| Max drawdown, 1 year | -38.8% | -34.4% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMLX is the largest of the group by market value.
- AMLX has returned the most over the past year.
- AMLX has been the calmest stock over the last 30 days.